Manjeet Paintlia to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Manjeet Paintlia has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
0.293
-
Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol. 2008 Dec; 214(2):168-80.
Score: 0.068
-
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol. 2006 Sep; 169(3):1012-25.
Score: 0.059
-
HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 2005 Sep; 19(11):1407-21.
Score: 0.055
-
Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res. 2004 Jul 01; 77(1):63-81.
Score: 0.051
-
Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-a-dependent mechanism. Glia. 2013 Sep; 61(9):1500-1517.
Score: 0.024
-
Activation of PPAR-? and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia. 2010 Nov 01; 58(14):1669-85.
Score: 0.020
-
Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia. 2009 Jan 15; 57(2):182-93.
Score: 0.017